Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251481 · ClinicalTrials.gov registry record · NA
Diffusion MRI for Head and Neck Cancer
A NA study of Head Cancer Neck, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT04251481: Active NA study of Head Cancer Neck, sponsored by NYU Langone Health.
NCT04251481 is a NA study of Head Cancer Neck that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251481, a NA study of Head Cancer Neck, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The proposed study is to investigate the feasibility of using quantitative diffusion MRI (dMRI) methods for accurate and comprehensive assessment of treatment response. dMRI is a powerful tool to probe treatment-induced change in tumors. It is a unique in vivo imaging technique sensitive to cellular microstructures at the scale of water diffusion length on the order of a few microns. Previous studies have shown that both diffusion coefficient D and diffusional kurtosis coefficient K are promising imaging markers of (i) cell viability which can be used for evaluation of early treatment response. However, it is often underappreciated that these dMRI metrics are not fixed constants, but rather functions of the diffusion time t, D(t) and K(t); their t-dependency is determined by tissue properties, such as cell size and membrane permeability of tissue. D(t) and K(t) of tumors can vary substantially depending on t in the range of diffusion times (30-100 ms) typically used in clinical scan.
Primary Outcome
Estimated components from a random effects model in each dMRI measure will be used to compute intra-class correlation as estimates of repeatability of each measure.
Conditions Studied
Interventions
- RADIATION PET/MRI with FDG
- RADIATION MRI scan without contrast
- RADIATION MRI with gadolinium
Study Locations (2)
New York
- NYU Langone - New York
- Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What the registry record for NCT04251481 still lists
NCT04251481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Head Cancer Neck appearing as the primary indexed condition, and to 3 interventions - of which PET/MRI with FDG is the first listed.
NCT04251481 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04251481 about?
NCT04251481 is a clinical study titled "Diffusion MRI for Head and Neck Cancer". The proposed study is to investigate the feasibility of using quantitative diffusion MRI (dMRI) methods for accurate and comprehensive assessment of treatment response. dMRI is a powerful tool to probe treatment-induced change in tumors. It is a unique in vivo imaging technique sensitive to cellular...
What is the current status of trial NCT04251481?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2019-10-16. Estimated completion is 2026-04-30.
What conditions does trial NCT04251481 study?
This clinical trial studies the following conditions: Head Cancer Neck.
What interventions are being tested in trial NCT04251481?
The interventions under investigation include: PET/MRI with FDG (RADIATION), MRI scan without contrast (RADIATION), MRI with gadolinium (RADIATION).
Who is sponsoring clinical trial NCT04251481?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04251481 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head Cancer Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04251481's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI